Toll Brothers to Webcast Its Fourth Quarter 2026 Earnings Conference Call Live on December 8, 2026 at 8:30 a.m. (ET)
results
View All ->
iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy Completed dosing in the single ascending dose portion of the Phase 1 clinical trial of IBIO-600 Plans to participate in upcoming scientific and investor conferences SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiop
Big Sky Industrial Inc. Reports Third Quarter 2026 Results and Highlights Phase 1 Construction Progress at Big Sky Carbon Hub
HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Big Sky Industrial Inc. (NASDAQ: BSIN) (“Big Sky Industrial” or the “Company”), an integrated industrial gas, energy, and carbon management company, today reported financial and operating results for the three and nine months ended September 30, 2026, while highlighting construction and development progress during the quarter at the Company’s Big Sky Carbon Hub, its flagship project in Montana. MANAGEMENT COMMENTS “The third quarter was about execution,
newsContext Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months Dose escalation to 420 µg every three weeks is ongoing following completion of the DLT assessment period at 280 µg Phase 1b initiation expected in Q1 2027 and initial Q3W efficacy data in Q2 2027 Cash and cash equivalents of $34.4 million as of September 30, 2026 expected to fund operations to early Q4 2027 PHILADELPHIA, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Context Ther
quarter
View All ->Toll Brothers to Webcast Its Fourth Quarter 2026 Earnings Conference Call Live on December 8, 2026 at 8:30 a.m. (ET)
Toll Brothers at Tesoro Highlands - Bella Terra Collection Santa Clarita, CA FORT WASHINGTON, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, will broadcast live on its website, www.TollBrothers.com , a conference call to discuss results for its fourth quarter ended October 31, 2026. The call is scheduled for 8:30 a.m. (ET) on Tuesday, December 8, 2026 and will be hosted by Douglas C. Yearley, Jr., Executive Chairman of the Boa
Stran & Company Reports 32% Increase in Third Quarter 2026 Gross Profit as Gross Margin Expands to 33.3%
Nine-Month Net Income of $1.1 Million, an Improvement of $2.1 Million Over the Prior-Year Period Conference Call to be Held Wednesday, November 11, 2026 at 10:00 a.m. Eastern Time QUINCY, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ: SWAG), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced its financial results for the three and nine months ended September
newsBig Sky Industrial Inc. Reports Third Quarter 2026 Results and Highlights Phase 1 Construction Progress at Big Sky Carbon Hub
HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Big Sky Industrial Inc. (NASDAQ: BSIN) (“Big Sky Industrial” or the “Company”), an integrated industrial gas, energy, and carbon management company, today reported financial and operating results for the three and nine months ended September 30, 2026, while highlighting construction and development progress during the quarter at the Company’s Big Sky Carbon Hub, its flagship project in Montana. MANAGEMENT COMMENTS “The third quarter was about execution,
third
View All ->
Stran & Company Reports 32% Increase in Third Quarter 2026 Gross Profit as Gross Margin Expands to 33.3%
Nine-Month Net Income of $1.1 Million, an Improvement of $2.1 Million Over the Prior-Year Period Conference Call to be Held Wednesday, November 11, 2026 at 10:00 a.m. Eastern Time QUINCY, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ: SWAG), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced its financial results for the three and nine months ended September
Big Sky Industrial Inc. Reports Third Quarter 2026 Results and Highlights Phase 1 Construction Progress at Big Sky Carbon Hub
HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Big Sky Industrial Inc. (NASDAQ: BSIN) (“Big Sky Industrial” or the “Company”), an integrated industrial gas, energy, and carbon management company, today reported financial and operating results for the three and nine months ended September 30, 2026, while highlighting construction and development progress during the quarter at the Company’s Big Sky Carbon Hub, its flagship project in Montana. MANAGEMENT COMMENTS “The third quarter was about execution,
newsContext Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months Dose escalation to 420 µg every three weeks is ongoing following completion of the DLT assessment period at 280 µg Phase 1b initiation expected in Q1 2027 and initial Q3W efficacy data in Q2 2027 Cash and cash equivalents of $34.4 million as of September 30, 2026 expected to fund operations to early Q4 2027 PHILADELPHIA, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Context Ther
reports
View All ->iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy Completed dosing in the single ascending dose portion of the Phase 1 clinical trial of IBIO-600 Plans to participate in upcoming scientific and investor conferences SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiop
Stran & Company Reports 32% Increase in Third Quarter 2026 Gross Profit as Gross Margin Expands to 33.3%
Nine-Month Net Income of $1.1 Million, an Improvement of $2.1 Million Over the Prior-Year Period Conference Call to be Held Wednesday, November 11, 2026 at 10:00 a.m. Eastern Time QUINCY, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ: SWAG), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced its financial results for the three and nine months ended September
newsBig Sky Industrial Inc. Reports Third Quarter 2026 Results and Highlights Phase 1 Construction Progress at Big Sky Carbon Hub
HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Big Sky Industrial Inc. (NASDAQ: BSIN) (“Big Sky Industrial” or the “Company”), an integrated industrial gas, energy, and carbon management company, today reported financial and operating results for the three and nine months ended September 30, 2026, while highlighting construction and development progress during the quarter at the Company’s Big Sky Carbon Hub, its flagship project in Montana. MANAGEMENT COMMENTS “The third quarter was about execution,
financial
View All ->iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update
Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy Completed dosing in the single ascending dose portion of the Phase 1 clinical trial of IBIO-600 Plans to participate in upcoming scientific and investor conferences SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiop
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months Dose escalation to 420 µg every three weeks is ongoing following completion of the DLT assessment period at 280 µg Phase 1b initiation expected in Q1 2027 and initial Q3W efficacy data in Q2 2027 Cash and cash equivalents of $34.4 million as of September 30, 2026 expected to fund operations to early Q4 2027 PHILADELPHIA, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Context Ther
newsPrecipio Announces Q3-2026 Financial Results
Record quarterly revenue, positive Adjusted EBITDA, and strong operating cash flow - all position Precipio for accelerated future growth NEW HAVEN, Conn., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces third-quarter financial results for the quarter ending September 30, 2026. Below are some of the key financial performance metrics for the Company. For additional results, please see the Company’s Form 10-Q filed today. Revenue – $7.3
Magazine Focus
The New Growth Playbook: Building Businesses for Sustainable Expansion
Growth is being redefined. Expanding revenue remains important, but businesses are placing greater emphasis on profitability, cash discipline, operational efficiency, customer retention and resilience. This edition explores the changing growth playbook and the foundations required for sustainable expansion. From technology and process design to capital allocation and market reach, it examines how businesses can pursue ambition without allowing complexity, costs or uncontrolled expansion to weaken the enterprise.
For years, growth was often discussed primarily in terms of size, speed and market share. The conversation is becoming more balanced. Strong businesses also need healthy economics, efficient operations and the ability to withstand uncertainty. This edition looks at growth through that wider lens and considers how organizations can expand with greater discipline, clarity and long-term purpose in practice.
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.